Simon D Kyle Selected Research

Sleep Initiation and Maintenance Disorders (Insomnia)

11/2022	The effect of sleep restriction therapy for insomnia on sleep pressure and arousal: a randomized controlled mechanistic trial.
1/2022	Psychological and behavioural interventions in bipolar disorder that target sleep and circadian rhythms: A systematic review of randomised controlled trials.
1/2022	Hypnotic and Melatonin/Melatonin-Receptor Agonist Treatment in Bipolar Disorder: A Systematic Review and Meta-Analysis.
1/2022	Daridorexant for insomnia disorder.
1/2022	Insomnia disorder: State of the science and challenges for the future.
1/2021	Insomnia as a mediating therapeutic target for depressive symptoms: A sub-analysis of participant data from two large randomized controlled trials of a digital sleep intervention.
1/2021	The acute effects of sleep restriction therapy for insomnia on circadian timing and vigilance.
1/2021	Reporting of adverse events in cognitive behavioural therapy for insomnia: A systematic examination of randomised controlled trials.
1/2021	The clinical effects of sleep restriction therapy for insomnia: A meta-analysis of randomised controlled trials.
10/2020	Cognitive behavioural therapy for insomnia does not appear to have a substantial impact on early markers of cardiovascular disease: A preliminary randomized controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simon D Kyle Research Topics

Disease

39	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2022 - 09/2011
3	Sleep Deprivation 01/2022 - 01/2019
3	Disorders of Excessive Somnolence (Hypersomnia) 01/2021 - 02/2014
3	Fatigue 01/2018 - 12/2016
2	Cognitive Dysfunction 01/2020 - 12/2016
1	Mania (Manias) 01/2022
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2020
1	Dementia (Dementias) 01/2019
1	Genetic Risk Score 01/2019
1	Sleepiness 01/2019
1	Restless Legs Syndrome (Restless Legs) 01/2019
1	Sleep Wake Disorders 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2017
1	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 01/2017
1	Mental Disorders (Mental Disorder) 12/2015
1	Pain (Aches) 09/2011

Drug/Important Bio-Agent (IBA)

4	Indicators and Reagents (Reagents)IBA 01/2019 - 03/2014
3	Biological ProductsIBA 01/2019 - 03/2015
2	Hypnotics and Sedatives (Sedatives)IBA 01/2022 - 12/2015
2	Silver Sulfadiazine (SSD)FDA LinkGeneric 11/2017 - 11/2016
1	daridorexantIBA 01/2022
1	MelatoninIBA 01/2022
1	Melatonin Receptors (Melatonin Receptor)IBA 01/2022
1	ORALIT (ORS)IBA 01/2021
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	N-(4-aminophenethyl)spiroperidol (NAPS)IBA 01/2019
1	salicylhydroxamic acid (SHAM)IBA 12/2018
1	Glutamine (L-Glutamine)FDA Link 11/2017
1	EnzymesIBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2016
1	Polymethyl Methacrylate (Sol)IBA 11/2016
1	ElementsIBA 10/2015
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2015
1	Starch SynthaseIBA 12/2012

Therapy/Procedure

26	Therapeutics 11/2022 - 09/2011
1	Drug Therapy (Chemotherapy) 01/2022
1	Phototherapy (Light Therapy) 01/2022
1	Chronotherapy 01/2022
1	Wearable Electronic Devices 12/2018
1	Exercise Therapy (Therapy, Exercise) 01/2017